Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

NADH

Reduced β-Nicotinamide Adenine Dinucleotide (NADH) · also known as Reduced nicotinamide adenine dinucleotide, NADH, PANMOL-NADH, β-NADH

NADH is an endogenous electron donor for mitochondrial complex I. There is no direct evidence on whether oral supplementation reaches the mitochondria intact. Human studies so far mostly combined it with coenzyme Q10, so their results cannot be attributed to NADH alone.

Typical dose: Enteric-coated stabilized NADH 10–20 mg/day, taken in the morning on an empty stomach
Absorption and forms: NADH is easily oxidized by stomach acid and by moisture in the air. Enteric-coated microencapsulated formulations help reduce breakdown by stomach acid, but there is no evidence that any particular patented microcapsule is required. How much intact NADH is absorbed after oral intake, and how it is distributed to tissues, is unclear.

Clinical uses and human evidence

Fatigue and energy

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Forsyth 1999 · Ann Allergy Asthma Immunol · Randomized crossover trial · n=26 — Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome
  2. Alegre 2010 · Rev Clin Esp · RCT · n=86 — [Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome]

Mechanisms of action

Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)

★☆☆☆☆Mechanism evidence: grade DSecondary target

NADH takes part in the endogenous BH4 reduction cycle, a known biochemical reaction, but this does not mean that oral supplementation produces the same effect. No human study has shown that usual oral NADH increases brain BH4 regeneration, tyrosine hydroxylase activity, or synaptic dopamine.

References (1)
  1. No direct study found · Literature search conclusion: no reliable human study has shown that usual oral NADH increases brain BH4 regeneration, tyrosine hydroxylase activity, or synaptic dopamine

Substrate and cofactor supply for glutathione (GSH) synthesis

★☆☆☆☆Mechanism evidence: grade DSecondary target

In the body, NADH can be converted to NADPH through transhydrogenation, supplying electrons to glutathione reductase. This is endogenous metabolism. It is unclear whether oral NADH reaches this step, and no human study has shown that 10–20 mg taken orally increases tissue NADPH or glutathione reduction.

References (1)
  1. No direct study found · Literature search conclusion: no reliable human study has shown that 10–20 mg of oral NADH increases tissue NADPH or glutathione reduction through transhydrogenation

Safety and drug interactions

A very small number of highly sensitive people may experience stimulation or mild difficulty falling asleep if they take it in the evening, so morning use on an empty stomach is recommended. Safety data in pregnancy, breastfeeding and long-term use are limited, so consult a doctor before use.
Open in the interactive app ›